Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ASCO20 Virtual Scientific Program
Autolus Therapeutics plc - American Depositary Shares (AUTL)
Last autolus therapeutics plc - american depositary shares earnings: 11/7 07:06 am
Check Earnings Report
US:NASDAQ Investor Relations:
autolus.com/investor-relations
Company Research
Source: GlobeNewswire
– Data continue to show encouraging clinical activity alongside tolerable safety to deliver a potentially highly differentiated product profile – Conference call and webcast to be held Monday, June 1, 2020 at 8:30 am EDT / 1:30 pm BST LONDON, May 29, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced new data highlighting progress on AUTO3, the company’s CAR T cell therapy being investigated in the ALEXANDER study, a Phase 1/2 study in relapsed/refractory diffuse large B cell lymphoma (DLBCL), during the Annual Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific Program beginning May 29. “Data from the ALEXANDER trial of AUTO3, a CD19/CD22 dual-targeting CAR T product candidate in DLBCL have shown a complete response rate of 63% at the recommended Phase 2 dose range with an excellent safety profile,” said Dr. Aravind Ramakrishnan, Medical Dir
Show less
Read more
Impact Snapshot
Event Time:
AUTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AUTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AUTL alerts
High impacting Autolus Therapeutics plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AUTL
News
- Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO [Yahoo! Finance]Yahoo! Finance
- Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCOGlobeNewswire
- Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024GlobeNewswire
- CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market to Showcase Significant Growth at a CAGR of 15% by 2032 | DelveInsightPR Newswire
- CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market to Showcase Significant Growth at a CAGR of 15% by 2032 | DelveInsightPR Newswire
AUTL
Earnings
- 11/2/23 - Miss
AUTL
Sec Filings
- 4/1/24 - Form 8-K
- 3/28/24 - Form S-3ASR
- 3/25/24 - Form SC
- AUTL's page on the SEC website